- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2019
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis ; volume:23 ; number:6 ; day:19 ; month:10 ; year:2021 ; pages:601-608 ; date:11.2021
Pediatric drugs ; 23, Heft 6 (19.10.2021), 601-608, 11.2021
- Creator
-
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40272-021-00476-w
- URN
-
urn:nbn:de:101:1-2022012818194385653756
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.08.2025, 4:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx) : frühe und effektive Behandlung mittelschwerer bis schwerer Plaque-Psoriasis
Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
Secukinumab(Plaque-Psoriasis) : Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse)
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-78
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx) : frühe und effektive Behandlung mittelschwerer bis schwerer Plaque-Psoriasis
Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
Secukinumab(Plaque-Psoriasis) : Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse)
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-78
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Secukinumab (Cosentyx) : frühe und effektive Behandlung mittelschwerer bis schwerer Plaque-Psoriasis
Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
Secukinumab(Plaque-Psoriasis) : Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse)
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V
Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-78
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry